Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/1034
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSantoso, Natasya Irene-
dc.date.accessioned2024-01-29T03:13:56Z-
dc.date.available2024-01-29T03:13:56Z-
dc.date.issued2024-01-18-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/1034-
dc.description.abstractTankyrase 1 has received attention as a promising target for anti-cancer therapies due to its upregulated expression in various cancer types. Its crucial role in PARsylation leads to the degradation of tumor suppressors (e.g. Axin, TRF1, and PTEN) through the ubiquitin-proteasome pathway, highlighting its significance in oncogenic processes. The urgency to discover novel tankyrase 1 inhibitors stems from concerns about potential off-target effects associated with existing inhibitors. Notably, there is currently no tankyrase 1 inhibitor in clinical use with a limited number of compounds are undergoing clinical trials. This study addressed this gap by identifying new potential tankyrase 1 inhibitors using a humanized yeast cell-based bioassay. It was found that both PPΔ and EPPΔ strains were deemed unsuitable and not functional for use in the screening system due to persistent drug resistance and the loss of the tankyrase 1 toxicity phenotype, respectively. Despite facing challenges with the screening system, compounds namely N20, N648, N661, and S73 exhibited growth rescue in yeast cells upon tankyrase 1 inhibition during the initial screening (conducted before the internship). Subsequent testing in the MTT assay for cancer cell viability highlighted N661 as the most potent inhibitor, followed by N648, which demonstrated a dose-dependent decrease in cancer cell viability. These findings suggest the promising potential of N661 and N648 as tankyrase 1 inhibitors, opening opportunities for the advancement of targeted therapies specifically designed for cases of tankyrase 1 overexpression.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesEP BM-026;EP24-068-
dc.subjecttankyrase 1en_US
dc.subjectcanceren_US
dc.subjectPARsylationen_US
dc.subjectyeast cell-based screening systemen_US
dc.subjecttankyrase 1 inhibitoren_US
dc.subjectS. cerevisiaeen_US
dc.titleIdentification Of Human Tankyrase 1 Inhibitors As Potential Anti-cancer Agents Using A Humanized Yeast Cell-based Bioassayen_US
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
Abstract.pdfAbstract65.57 kBAdobe PDFView/Open
Chapter 1.pdfChapter 173.85 kBAdobe PDFView/Open
Cover.pdfCover142.69 kBAdobe PDFView/Open
EP2024_BM_Natasya Irene Santoso.pdf
  Restricted Access
Full Text2 MBAdobe PDFView/Open Request a copy
References.pdfReferences144.97 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.